A Phase III, Prospective, Randomised, Open Label Study to Compare the Efficacy and Safety of Lanreotide Autogel 60, 90 or 120 mg With Lanreotide 40 mg PR in Subjects With Active Acromegaly

Trial Profile

A Phase III, Prospective, Randomised, Open Label Study to Compare the Efficacy and Safety of Lanreotide Autogel 60, 90 or 120 mg With Lanreotide 40 mg PR in Subjects With Active Acromegaly

Completed
Phase of Trial: Phase III

Latest Information Update: 02 Mar 2017

At a glance

  • Drugs Lanreotide (Primary)
  • Indications Acromegaly
  • Focus Therapeutic Use
  • Acronyms LANTERN
  • Sponsors Ipsen
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 27 Feb 2017 Status changed from active, no longer recruiting to completed.
    • 30 Jun 2016 Planned End Date changed from 1 Apr 2017 to 1 Jan 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top